In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer ...

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

UBS analyst Jo Walton maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

Exscientia (EXAI) announced the advancement of two additional discovery programs within its collaboration with Sanofi (SNY), ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after ...